Changes in Plasma TIMP-1 Levels after Resection for Primary Colorectal Cancer

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 75-81

  Frederiksen, Camilla ^a,f   Lomholt, A F ^a   Davis, G J ^b   Dowell, B L ^b   Blankenstein, M A ^c   Christensen, I J ^d   Brunner, N ^e   Nielsen, H J ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ABBOTT LABORATORIES   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d FINSEN LABORATORY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biological marker; CEA; Immunoassay; Lead time; Postoperative follow up; TIMP 1

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ANALYZER; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; IMMUNOASSAY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 61449147267     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamartz R, Peltomaki P, Sturgeon C and Topolcan O: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360, 2007.
2. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, MacDonald JS, Somerfield MR, Hayes DF and Bast RC: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.
3. Jeffery M, Hickey BE and Hider PN: Follow-up strategies for patients treated for non-metastatic colorectal cancer. Crochrane Database Syst Rev 1: CD002200, 2007.
4. Figueredo A, Rumble RB, Maroun J, Earle C, Cummings B, McLeod R, Zuraw L and Zwaal C, for the members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Follow-up of patients with curatively resected colorectal cancer: A practice guideline. BMC Cancer 3: 26, 2003.
5. Greene FL: Staging of colon and rectal cancer: From endoscopy to molecular markers. Surg Endosc 20(Suppl 2): S475-S478, 2006.
6. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA and Sobin LH: The process for continuous improvement of the TNM classification. Cancer 100: 1-5, 2004
7. Poster DG, Benson AB III and Somerfield MR: Surveillance Strategies after Curative Treatment of Colorectal Cancer. N Engl J Med 350: 2375-2382, 2004.
8. McArdle C: ABC of colorectal cancer: effectiveness of Follow-Up. BMJ 321: 1332-1335, 2000.
9. Renehan AG, Egger M, Saunders MP and O'Dwyer ST: Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324: 813-818, 2002.
10. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
11. Liu XW, Bernardo MM, Fridman R and Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signalling pathway. J Biol Chem 278: 40364-40372, 2003.
12. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A and Stetler-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 2002-2010, 1998.
13. Bertaux B, Hornebeck W, Eisen AZ and Dubertret L: Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97: 679-685, 1991.
14. Murate T, Yamashita K, Ohashi H, Kagami Y, Tsushita K, Kinoshita T, Hotta T, Saito H, Yoshida S and Mori KJ: Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin- responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity. Exp Hematol 21: 169-176, 1993.
15. Reed MJ, Koike T, Sadoun E, Sage EH and Puolakkainen P: Inhibition of TIMP1 enhances angiogenesis in vivo and cell migration in vitro. Microvascular Research 65: 9-17, 2003.
16. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W and Brunner N: High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6: 4292-4299, 2000.
17. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N and Stephens RW: Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80: 495-503, 1999.
18. Waas ET, Hendriks T, Lomme RM and Wobbes T: Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48: 700-710, 2005.
19. Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, Noguchi Y and Takanashi Y: Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Br J Surg 88: 1596-1601, 2001.
20. Wurtz SO, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V and Brunner N: Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol Cell Proteomics 4: 483-491, 2005.
21. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N and Foekens JA: Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10: 2289-2298, 2004.
22. Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Creme E, Wurtz A, Porte H and Huet G: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent. Cancer 103: 1676-1684, 2005.
23. Hofmann UB, Westphal JR, van Muijen GN and Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol 115: 337-344, 2000.
24. Hammer JH, Basse L, Svendsen MN, Werther K, Brunner N, Christensen IJ and Nielsen HJ: Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer. Colorectal Dis 8: 168-172, 2006.
25. Holten-Andersen MN, Nielsen HJ, Sorensen S, Jensen V, Brunner N and Christensen IJ: Elevated postoperative plasma levels of tissue inhibitor of metalloproteinases-1 predict minimal residual disease in patients with colorectal cancer. Eur J Cancer 42: 1889-1896, 2006.
26. Greene FL, Stewart AK and Norton HJ: A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 236: 416-421, 2002.
27. Lomholt AF, Frederiksen CB, Christensen IJ, Brunner N and Nielsen HJ: Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta 380: 128-132, 2007.
28. Quinn FA: ARCHITECT 12000 and 12000SR analyzers. The imunnoassay Handbook. 3rd edition:pp128-147, Amsterdam: Elsevier, 2005.
29. Davis GJ, Chans S, Biegalski T, Hemken P and Dowell B: Tissue inhibitor of metalloproteinases-1 : Performance of an Abbott Architect Research use only (RUO) assay. Tumour Biol 27(Suppl2): 598, 2006.
30. ARCHITECT CEA reagents package insert. 68-5597/R1, 2007.
31. Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N and Nielsen HJ: Assessment of the biological variation of plasma Tissue Inhibitor of Metalloproteinases-1. Int J Biol Markers 23: 42-47, 2008.
32. Goldstein MJ and Mitchell EP: Carcinoembryonic antigen in the staging and Follow-Up of patients with colorectal cancer. Cancer Invest 23: 338-351, 2005.
33. Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brunner N and Fernebro E: Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study. Eur J Cancer 40: 64-72, 2004.
34. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sorensen S, Overgaard J, Lilja H, Harris A, Murphy G and Brunner N: Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8: 156-164, 2002.
35. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R and Murray GI: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10: 8229-8234, 2004.
36. Oberg A, Hoyhtya M, Tavelin B, Stenling R and Lindmark G: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 20: 1085-1091, 2000.
37. Holten-Andersen MN, Brunner N, Christensen IJ, Jensen V and Nielsen HJ: Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. Scand J Clin Lab Invest 62: 223-230, 2002.
38. Murate T, Yamashita K, Isogai C, Suzuki H, Ichihara M, Hatano S, Nakahara Y, Kinoshita T, Nagasaka T, Yoshida S, Komatsu N, Miura Y, Hotta T, Fujimoto N, Saito H and Hayakawa T: The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol 99: 181-189, 1997.
39. Hildebrandt U, Kessler K, Plusczyk T, Pistorius G, Vollmar B and Menger MD: Comparison of surgical stress between laparoscopic and open colonie resections. Surg Endosc 17: 242-246, 2003.
40. Ytting H, Christensen IJ, Basse L, Lykke J, Thiel S, Jensenius JC and Nielsen HJ: Influence of major surgery on the mannan-binding lectin pathway of innate immunity. Clin Exp Immunol 144: 239-246, 2006.
41. Trengove NJ, Stacey MC, Macauley S, Bennett N, Gibson J, Burslem F, Murphy G and Schultz G: Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair and Regeneration 7: 442-452, 1999.
42. Baker EA and Leaper DJ: Profiles of matrix metalloproteinases and their tissue inhibitors in intraperitoneal drainage fluid: Relationship to wound healing. Wound Repair and Regeneration 11: 268-274, 2003.
43. Robins SP, Milne G, Duncan A, Davies C, Butt R, Greiling D and James IT: Increased skin collagen extractability and proportions of collagen type III are not normalized after 6 months healing of human excisional wounds. J Invest Dermatol 121: 267-272, 2003.
44. Berman JM, Cheung RJ and Weinberg DS: Surveillance after colorectal cancer resection. Lancet 355: 395-399, 2000.
45. Duffy MJ: Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful? Clin Chem 47: 624-630, 2001.